Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Advicenne Logo
Advicenne Growth Score
79
CB Rank
67944
Heat Score
49
Advicenne is a specialty pharmaceutical company dedicated to improving the lives of patients who suffer from rare kidney diseases.
Founded
obfuscation
PublicPost-IPO Equity Paris, Ile-de-France, France11-50 advicenne.com
Biotechnology
Medical
Pharmaceutical
Therapeutics
Overview

Advicenne
Total Funding
obfuscation
Growth Score
79
Heat Score
49

Total Funding
obfuscation
obfuscation
Post-IPO Equity raised
obfuscation
Growth Score79
-12 pts
in past quarter
Heat Score 49
18 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Advicenne

CB Rank
67944
Advicenne is a specialty pharmaceutical company dedicated to improving the lives of patients who suffer from rare kidney diseases.
Founded
obfuscation
PublicPost-IPO Equity Paris, Ile-de-France, France11-50 advicenne.com
Biotechnology
Medical
Pharmaceutical
Therapeutics

Funding Rounds

Post-IPO Equity
OBF
in
obfuscation
Post-IPO Debt
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation

Key People

Details

Legal Name Advicenne LLC
Operating Status Active
Stock Symbol  EPA:ADVIC
Company Type For Profit
Founders  Caroline Roussel-Maupetit, Luc Andre Granier
About the Company

Since its founding in 2007, Advicenne has been dedicated to developing and commercializing innovative treatments that address unmet medical needs in the area of nephrology. Our lead drug candidate, ADV7103, is in late-stage clinical trials for two indications: distal renal tubular acidosis (dRTA) and cystinuria. Listed on both the Euronext Paris

and Euronext Brussels stock exchanges, the company is headquartered in Nîmes, France.

Phone Number +33 (0)1 85 73 36 20
Contact Email contact@advicenne.com
Predictions & Insights

Growth Insight

See this Growth Insight
Advicenne is
Lorem
 to be growing
Top Contributing Factors
Recently Raised Funding

Products & Services

ADV7103 for distal renal tubular acidosis (dRTA)
An oral prolonged-release drug for treating distal renal tubular acidosis in children and adults, designed for twice-daily intake to maintain blood pH balance.
ADV7103 for cystinuria
An investigational oral treatment for cystinuria, designed to improve efficacy, safety, and patient compliance in managing this rare kidney condition.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 6
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Advicenne Logo
Post-IPO Equity - Advicenne
1
obfuscation
BpifrancePost-IPO Equity
obfuscation
Post-IPO Equity - Advicenne Logo
Post-IPO Equity - Advicenne
1
obfuscation
BpifrancePost-IPO Equity
obfuscation
Post-IPO Equity - Advicenne Logo
Post-IPO Equity - Advicenne
1
obfuscation
BpifrancePost-IPO Equity
obfuscation
Post-IPO Equity - Advicenne Logo
Post-IPO Equity - Advicenne
1
obfuscation
BpifrancePost-IPO Equity
obfuscation
Post-IPO Equity - Advicenne Logo
Post-IPO Equity - Advicenne
1
obfuscation
BpifrancePost-IPO Equity

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 6
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Advicenne Logo
Post-IPO Equity - Advicenne
1
obfuscation
BpifrancePost-IPO Equity
obfuscation
Post-IPO Equity - Advicenne Logo
Post-IPO Equity - Advicenne
1
obfuscation
BpifrancePost-IPO Equity
obfuscation
Post-IPO Equity - Advicenne Logo
Post-IPO Equity - Advicenne
1
obfuscation
BpifrancePost-IPO Equity
obfuscation
Post-IPO Equity - Advicenne Logo
Post-IPO Equity - Advicenne
1
obfuscation
BpifrancePost-IPO Equity
obfuscation
Post-IPO Equity - Advicenne Logo
Post-IPO Equity - Advicenne
1
obfuscation
BpifrancePost-IPO Equity

Investors

Market Intelligence
People
View Profiles & Contacts
Headcount 11-50 Employee Profiles 2 Board Members and Advisors 1 Contacts 3

Employee Profiles

Board Members and Advisors

News

News and Press

News•Jun 1, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jun 1, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 21, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 5, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

473
443.68%
 in past month

IT Spend

$180.1KThis year, Advicenne is projected to spend $180.1K on IT, according to Aberdeen.

Actively Used Products

7Advicenne uses 7 technology products and services including HTML5, Google Maps API, and  Google Analytics, according to G2 Stack.

Active Website Tech Count

4Advicenne is actively using 4 technologies for its website, according to BuiltWith. These include Google Maps, CommonCrawl Top 5m, and  CommonCrawl Top 10m.

Total IP

19The intellectual property of Advicenne includes 8 registered patents primarily in the 'Medical Or Veterinary Science; Hygiene' category, according to IPqwery. Additionally, Advicenne has registered 11 trademarks with the most popular class being 'Pharmaceutical, veterinary and sanitary products', according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is Advicenne's headquarters? Advicenne is located in Paris, Ile-de-France, France.Who invested in Advicenne? Advicenne has 8 investors including Bpifrance and  European Investment Bank.When was the last funding round for Advicenne? Advicenne closed its last funding round on
obfuscation
from a Post-IPO Equity round.Who are Advicenne's competitors? Alternatives and possible competitors to Advicenne may include Fresenius Medical Care, Abionyx Pharma, and  GENFIT.How much funding has Advicenne raised to date? Advicenne has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(05b78c5 1)
|